It wasn't so long ago that Intuitive Surgical (Nasdaq:ISRG) was one of the cleanest growth stories in med-tech, as hospitals seemingly couldn't buy the company's surgical robots fast enough. Not only did Intuitive's daVinci robot come to all but dominate the prostatectomy market, but it was well on its way to taking significant share in hysterectomy as well. Then the bad news began. From reports of surgical complications to multiple papers alleging that robotic surgery is not cost-effective, the news flow turned decidedly negative even as procedure counts continued to grow. Now we have a major quarterly earnings miss to digest. While there are enough rumblings out there to suggest that it's not a solely Intuitive-specific issue and the procedure growth numbers still look decent, it looks this highly-valued stock is going back into the penalty box. I do believe Intuitive continues to offer above-average growth in the med-tech space, though, and the reality is that this stock only seems to get cheap when the news flow gets pretty scary. A Big Miss For Q2, But Maybe Not Where You'd ExpectIntuitive Surgical doesn't miss very often, so the company's warning that second quarter earnings would significantly miss expectations is rare enough all on its own. Against an average estimate of about $630 million, Intuitive management is calling for $575 million in revenue in the quarter – a 9% miss that is also about 6% below the lowest estimate on the Street. Although the company didn't give EPS guidance, the net income number would suggest an EPS miss of similar magnitude assuming that the company didn't repurchase a huge number of shares during the quarter. So what happened? On first blush, it's tempting to think that Intuitive is finally falling victim to all of the bad press. The combination of more conservative prostate cancer management and the growth of new drugs like Johnson & Johnson's (NYSE:JNJ) Zytiga and Medivation's (Nasdaq:MDVN) Xtandi has been reducing prostatectomy volumes, and it sounds as though more conservative management is coming into vogue for hysterectomy cases as well. Couple that with a steady drumbeat of negative press about robot-assisted surgical complications and the cost-benefit of these procedures, and maybe hospitals are easing back on the reins. I don't know about that. Although instrument/accessory growth of 18% suggests some softness in procedure volumes, it's not nearly enough to account for the miss. On the other hand, US system placements plunged almost 30% to 90 (against an expectation of about 120 to 125) and total system placements declined (from 150 last year to 143) for the first time since the miserable capital equipment market of 2009. SEE: A Checklist For Successful Medical Technology InvestmentIs Intuitive Surgical No Longer Special?That there is pressure in the med-tech cap-ex space is not exactly news. Radiation oncology Varian (NYSE:VAR) has been seeing iffy order patterns, and other vendors of permanent (or semi-permanent) equipment like General Electric (NYSE:GE), Philips (NYSE:PHG), and CareFusion (NYSE:CFN) have been getting more cautious. What is news is that it's impacting Intuitive Surgical – a company that heretofore often seemed impervious to the economic conditions that affect demand for hospital cap-ex. But it may also not be an “either or” situation. As prostatectomy and hysterectomy volumes weaken, hospital administrators are likely not seeing nearly so much pressure to buy additional units. Likewise, pushback from payors may be leading hospitals to take more of a “start slow and go from there” approach with new units – making sure that a new daVinci system is fully utilized before shelling out the $1.5 million-plus for a new system. The Bottom LineIntuitive's stock is getting hammered today, but it won't really be clear what's going on in the market until we hear from others in the space like Stryker (NYSE: SYK) and Covidien (NYSE:COV) and get a better sense of what is going in terms of surgery volumes, cap-ex, and so on. What's more, even with this expected decline it is not as though Intuitive will look cheap by traditional metrics like EV/EBTIDA or P/E. All of that said, more risk-tolerant investors who've been waiting for a chance to get into Intuitive shares may welcome this opportunity. I continue to believe that the Intuitive platform offers a compelling proposition for doing procedures on a minimally-invasive basis that would otherwise have to be done as open surgeries, with the attendant risks, pain, side-effects and so on. Accordingly, I think that so long as the utilization numbers hold up, this is a stock worth considering on weakness.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  8. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!